{"url_path":"/sec/cers/10-k/2026/item-2","section_key":"item-2","section_title":"Item 2 Properties","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-03-02","source_url":"https://www.sec.gov/Archives/edgar/data/1020214/0001193125-26-085678-index.html","accession_number":"0001193125-26-085678","cik":"0001020214","ticker":"CERS","issuer_name":"CERUS CORP","edgar_url":"https://www.sec.gov/Archives/edgar/data/1020214/0001193125-26-085678-index.html","primary_entity_key":"0001020214","primary_entity_name":"CERUS CORP"},"word_count":126,"has_tables":true,"body_markdown":"Item 2. Properties\n\nOur corporate headquarters, which includes our principal executive offices, is located in Concord, California. We lease this facility, which includes 84,631 square feet and includes laboratory space for blood safety research and supports general administrative, marketing and technical support functions. Of the 84,631 square feet, we ceased using approximately 15,000 square feet of rentable area of corporate office building in the third quarter of 2023. We are currently marketing our vacant space, though there continues to be more supply than demand for office space in the San Francisco Bay Area. We also lease an office facility in Amersfoort, the Netherlands, which is used for selling and administrative functions. We believe that our current and future facilities will be adequate for the foreseeable future."}